Aspen targets further Chinese acquisitions

accreditation
Share your Subscriber Article
You have 5 articles to share every month. Send this story to a friend!

Johannesburg - Aspen Pharmacare Holdings [JSE:APN] is seeking further acquisitions and adding salespeople in China as Africa’s biggest maker of generic drugs targets the world’s most populous country as a major growth market.

"China now is very much on our radar," deputy chief executive officer Gus Attridge said by phone on Wednesday.

In the past, "we may have avoided China because of our absence of representation there. But now China is going to be very much in scope."

Support independent journalism
Subscribe to News24 for just R75 per month to read all our investigative and in-depth journalism.
Subscribe
Already a subscriber? Sign in
Rand - Dollar
14.25
+0.3%
Rand - Pound
19.78
-0.2%
Rand - Euro
16.95
-0.0%
Rand - Aus dollar
10.71
-0.1%
Rand - Yen
0.13
+0.1%
Gold
1,783.59
+1.1%
Silver
26.01
+0.8%
Palladium
2,506.01
+1.6%
Platinum
1,040.00
+0.1%
Brent Crude
73.51
+0.6%
Top 40
59,488
-0.0%
All Share
65,574
-0.1%
Resource 10
60,963
+0.0%
Industrial 25
88,066
+0.1%
Financial 15
12,891
-0.8%
All JSE data delayed by at least 15 minutes Iress logo
Company Snapshot
Voting Booth
Should government have assigned a majority shareholding in SAA to the private sector?
Please select an option Oops! Something went wrong, please try again later.
Results
Yes, It's a good decision
64% - 203 votes
Not a good move
10% - 31 votes
Too early to tell
26% - 82 votes
Vote